| Cell line name | HG2L6.1c3 |
|---|---|
| Accession | CVCL_DC31 |
| Resource Identification Initiative | To cite this cell line use: HG2L6.1c3 (RRID:CVCL_DC31) |
| Comments | Population: Caucasian. Biotechnology: Cell line developed for CALUX (Chemically Activated LUciferase eXpression) bioassay. CALUX is used for rapid screening of samples for the presence of dioxin/TCDD-like compounds and AhR agonists/antagonists. Characteristics: Acts through the activation of a luciferase gene under the control of dioxin-response elements (DREs). Transfected with: UniProtKB; P08659; Firefly luciferase. Derived from sampling site: Liver. |
| Sequence variations | Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Leu (c.182A>T); ClinVar=VCV000375874; Zygosity=Heterozygous (from parent cell line).Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line). |
| Disease | Hepatoblastoma (NCIt: C3728) Hepatoblastoma (ORDO: Orphanet_449) |
| Species of origin | Homo sapiens (Human)
(NCBI Taxonomy: 9606)
|
| Hierarchy | Parent: CVCL_0027 (Hep-G2) |
| Sex of cell | Male |
| Age at sampling | 15Y |
| Category | Cancer cell line |
| Publications | PubMed=21394221; DOI=10.1007/s11426-010-0142-8 |
| Cross-references | |
| Other | Wikidata; Q54885926 |
| Entry history | |
| Entry creation | 13-Jul-2016 |
| Last entry update | 20-May-2021 |
| Version number | 12 |